Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients

Journal of Human Hypertension

Volumn 26, Issue 3, 2012, Pages 171-177

  Lacchini, R ^a   Jacob Ferreira, A L B ^a   Luizon, M R ^b   Gasparini, S ^a   Ferreira Sae, M C S ^a   Schreiber, R ^a   Nadruz Jr , W ^a   Tanus Santos, J E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Heart remodelling; left ventricular hypertrophy; MMP 2 haplotypes; MMP 2 polymorphisms

Indexed keywords

GELATINASE A;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEART LEFT VENTRICLE ENDDIASTOLIC DIAMETER; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE MASS INDEX; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; REGULATORY MECHANISM; RISK FACTOR;

ADULT; AGED; ECHOCARDIOGRAPHY; FEMALE; HAPLOTYPES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; POLYMORPHISM, GENETIC; VENTRICULAR REMODELING;

EID: 84857053373     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.8     Document Type: Article

References (34)

1. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79. (Pubitemid 38249147)
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566. (Pubitemid 20176696)
3. Fielitz J, Leuschner M, Zurbrugg HR, Hannack B, Pregla R, Hetzer R et al. Regulation of matrix metallo-proteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med 2004; 82: 809-820.
4. Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C et al. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem 2010; 116: 63-72.
5. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al. Matrix metallopro-teinases/tissue inhibitors of metalloproteinases: rela-tionship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089-2096.
6. Janicki JS, Brower GL, Gardner JD, Chancey AL, Stewart Jr JA. The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev 2004; 9: 33-42. (Pubitemid 38196075)
7. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004; 44: 1609-1618. (Pubitemid 39369793)
8. Rizzi E, Castro MM, Prado CM, Silva CA, Fazan Jr R, Rossi MA et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 2010; 16: 599-608.
9. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285-1342. (Pubitemid 350041472)
10. Manso H, Krug T, Sobral J, Albergaria I, Gaspar G, Ferro JM et al. Variants of the Matrix Metalloprotei-nase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke. BMC Med Genet 2010; 11: 40.
11. Singh R, Srivastava P, Srivastava A, Mittal RD. Matrix metalloproteinase (MMP-9 and MMP-2) gene polymorphisms influence allograft survival in renal transplant recipients. Nephrol Dial Transplant 2010; 25: 3393-3401.
12. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004; 64: 7622-7628. (Pubitemid 39372109)
13. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001; 276: 7549-7558.
14. Langers AM, Sier CF, Hawinkels LJ, Kubben FJ, van Duijn W, van der Reijden JJ et al. MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br JCancer 2008; 98: 1820-1823. (Pubitemid 351748845)
15. Pannu H, Kim DH, Guo D, King TM, Van Ginhoven G, Chin T et al. The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms. J Neurosurg 2006; 105: 418-423. (Pubitemid 44358753)
16. Mizon-Gerard F, de Groote P, Lamblin N, Hermant X, Dallongeville J, Amouyel P et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 2004; 25: 688-693. (Pubitemid 38579498)
17. Gai X, Zhang Z, Liang Y, Chen Z, Yang X, Hou J et al. MMP-2 and TIMP-2 gene polymorphisms and suscept-ibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease. Clin Chim Acta 2010; 411: 719-724.
18. Bauters C, Lamblin N, Ennezat PV, Mycinski C, Tricot O, Nugue O et al. A prospective evaluation of left ventricular remodeling after inaugural anterior myo-cardial infarction as a function of gene polymorphisms in the renin-angiotensin-aldosterone, adrenergic, and metalloproteinase systems. Am Heart J 2007; 153: 641-648. (Pubitemid 46440689)
19. Powell JT. Genes predisposing to rapid aneurysm growth. Ann N YAcad Sci 2006; 1085: 236-241. (Pubitemid 47092013)
20. Sales ML, Ferreira MC, Leme Jr CA, Velloso LA, Gallani MC, Colombo RC et al. Non-effect of p22-phox -930A/G polymorphism on end-organ damage in Brazilian hypertensive patients. J Hum Hypertens 2007; 21: 504-506. (Pubitemid 46813603)
21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108. (Pubitemid 43257193)
22. Lauer MS, Anderson KM, Larson MG, Levy D. A new method for indexing left ventricular mass for differences in body size. Am J Cardiol 1994; 74: 487-491. (Pubitemid 24269970)
23. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambig-uous. Am JHum Genet 2002; 70: 425-434. (Pubitemid 34112296)
24. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198: 320-331. (Pubitemid 351707391)
25. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metallopro-teinases in hypertensive vascular remodeling. Matrix Biol 2010; 29: 194-201.
26. Castro MM, Rizzi E, Rodrigues GJ, Ceron CS, Bendhack LM, Gerlach RF et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009; 46: 1298-1307.
27. Martinez ML, Castro MM, Rizzi E, Fernandes K, Demacq C, Bendhack LM et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur JPharmacol 2008; 591: 224-230.
28. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003; 33: 648-656. (Pubitemid 36918626)
29. Kandasamy AD, Chow AK, Ali MA, Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 2010; 85: 413-423.
30. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodel-ing in mice with chronic pressure overload. Hyperten-sion 2006; 47: 711-717. (Pubitemid 43740243)
31. Murphy G, Nagase H. Progress in matrix metallopro-teinase research. Mol Aspects Med 2008; 29: 290-308.
32. Lacchini R, Jacob-Ferreira AL, Luizon MR, Coeli FB, Izidoro-Toledo TC, Gasparini S et al. Matrix metallo-proteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta 2010; 411: 1940-1944.
33. Roldan V, Marin F, Gimeno JR, Ruiz-Espejo F, Gonzalez J, Feliu E et al. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopa-thy. Am Heart J 2008; 156: 85-91. (Pubitemid 351862294)
34. Schulz R. Intracellular targets of matrix metalloprotei-nase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007; 47: 211-242.